Brief: Sandoz Signs Global License Agreement With Eirgenix To Commercialize Pertuzumab
12/11/2025 06:38
Nov 12 (Reuters) - SANDOZ GROUP AG SDZ.S: SIGNS GLOBAL LICENSE AGREEMENT TO COMMERCIALIZE BREAST CANCER BIOSIMILAR PERTUZUMAB UNDER TERMS OF AGREEMENT, SANDOZ HAS EXCLUSIVE WORLDWIDE COMMERCIAL RIGHTS TO A BIOSIMILAR OF PERTUZUMAB, EXCLUDING CERTAIN COUNTRIES IN ASIA AGREEMENT WITH EIRGENIX INC Source text: ID:nEQgbgp6a Further company coverage: SDZ.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))